Increasing Ionic Calcium Inhibits Myeloma Cell Growth and its Progression in Mouse. Syed Hassan Mehdi¹, Alex Lee², Paul K Lee², Donghoon Yoon¹ ¹ Myeloma Center, the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA; ²CBHI (Calcium & Bone Health Institute, Canada), Coquitlam, British Colombia, Canada Multiple myeloma (MM) is the second most […]
CBHI News & Innovation
Clinical collaborative research
“SAC-SG: 2024 Product of the Year Winner”
Health & Wellness Category
“Your Living Bones”
The AANP 2023 Annual Convention
Introducing SAC-SG:
A One-of-a-Kind SAC Bound Glucose
Introduction to SAC Calcium & Its Implications for Treatment of AIDS/HIV
Calcium Signaling Dysfunction
& Ionic Calcium Therapy
Evaluation and Comparison of SAC
in the Progression of Multiple Myeloma
SAC Technology Applied
Cream’s Effect on Epithelial Cells
SAC Enhances Skin Protection
by Thickening Epidermis
Study of SAC Effects
in the Epithelial Cell Multiplication
CBHI’s latest AIC Technology was introduced by Dr. Jimenez
Clinical collaborative research
of CBHI and Hallym University
SAC Technology
Sigma Anti-bonding Calcium (Supplement Grade) SAC calcium helps protein bound calcium be ionized. Calcium in serum exists in three forms-40% of calcium binding protein, 10% of inorganic calcium, and 50% of ionized calcium. Only ionized calcium is the physiologically active form and can be absorbed in our bones by stimulating hormones which trigger the activity […]
AIC Technology
Anti-orbital Ionic Calcium (Medical Grade) What is the AIC? Medical grade AIC, is used for Anti-orbital Ionic Calcium Therapy (AICT). AIC pushes the threshold of purity level to 99.9%. Comparing it with SAC, AIC has a significantly higher absorption rate and achieving SAC’s highest physiological effects. Thousands of clinics around the world currently practice AICT. […]
Our Service
Current major services provided by CBHI The CBHI is an independent institution in calcium and bone health to develop better dietary supplements for patients with calcium related diseases, especially osteoporosis. The CBHI has measured bone mineral density of our clients by Quantitative Ultrasound Test (Sunlight miniomni, Israel) since 2013. We chose a longitudinal study in […]
Articles
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass Context: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. Objective: The aim was to determine the effects of prior denosumab or placebo injections […]
To evaluate the safety and efficacy of romosozumab in men with osteoporosis
To evaluate the safety and efficacy of romosozumab in men with osteoporosis Context: Globally, one in five men aged.50 years is predicted to experience an osteoporotic fracture. Because of the treatment gap in osteoporosis and the paucity of bone-forming agents for men, new osteoporosis treatments are needed. Objective: To evaluate the safety and efficacy of […]
Calcium signalling in T cells
Calcium signaling in T cells Calcium (Ca2+) signaling is of paramount importance to immunity. Regulated increases in cytosolic and organellar Ca2+ concentrations in lymphocytes control complex and crucial effector functions such as metabolism, proliferation, differentiation, antibody and cytokine secretion and cytotoxicity. Altered Ca2+ regulation in lymphocytes leads to various autoimmune, inflammatory and immunodeficiency syndromes. Several […]